300497 Jiangxi Fushine Pharmaceutical
- 10.68
- -0.54-4.81%
Jiangxi Fushine Pharmaceutical News
Express News | Fuxiang Pharmaceutical signed a strategic cooperation agreement with Greenker League and others
Express News | Fuxiang Pharmaceutical and others signed strategic cooperation agreements involving the development and supply of microbial proteins
The synthetic biology concept opened low and went up and down, and Sanyuan Biotech, Fuxiang Pharmaceutical, Meibang Technology, Chengzhi Co., Ltd., and Walter Co., Ltd. followed suit.
The synthetic biology concept opened low and went up and down, and Sanyuan Biotech, Fuxiang Pharmaceutical, Meibang Technology, Chengzhi Co., Ltd., and Walter Co., Ltd. followed suit.
Fuxiang Pharmaceutical (300497.SZ): “Artificial meat” is one of the main application areas of microbial proteins that the company has mass-produced
Gelonghui, May 11 | Fuxiang Pharmaceutical (300497.SZ) said on the investor interactive platform that “artificial meat” is one of the main application areas of microbial proteins that the company has mass-produced. In addition, the company's microbial protein can also be widely used in protein drinks, health foods, specialty foods, pet food, etc., and has characteristics such as high protein, high dietary fiber, low sugar, low fat, zero cholesterol, zero trans fatty acids, etc., and has been tested to contain 18 kinds of amino acids needed by the human body.
Express News | Fuxiang Pharmaceutical: Self-built multi-functional synthetic bio-biological fermentation production line
Fuxiang Pharmaceutical (300497.SZ): Currently building its own multi-functional synthetic bio-biological fermentation production line
Gelonghui, May 9 | Fuxiang Pharmaceutical (300497.SZ) said on the investor interactive platform that synthetic biology is an emerging discipline that uses renewable biomass as raw materials and organisms as production media to transform or create artificial life systems. Synthetic biology has characteristics such as being clean, efficient, and renewable. It has the potential to completely disrupt the current pattern at both the level of technology and industrial innovation, and is an important development direction for the company. Currently, the company has built its own multi-functional synthetic bio-biological fermentation production line, and has accumulated deep experience in biological fermentation technology, which is mainly used in the fields of medicine and food. The company's various enzyme preparations, hydroxyproline
Fuxiang Pharmaceutical (300497.SZ): Actual controller Bao Jianhua completed an increase of 2.351,000 shares
Gelonghui, May 7 | Fuxiang Pharmaceutical (300497.SZ) announced that as of the announcement date, Mr. Bao Jianhua, the controlling shareholder, actual controller and chairman of the company, had increased his holdings by 2.351,000 shares through centralized bidding, to an increase of 25.134,400 yuan. His current holdings increase plan has been completed.
Express News | Fuxiang Pharmaceutical: Using synthetic biology technology for microbial protein products, 1,200 tons of orders were received
The synthetic biology concept continued to be strong. Blue Biotech had 3 consecutive sales, Channing Biotech surged 15%, and Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou had advanced gains.
The synthetic biology concept continued to be strong. Blue Biotech had 3 consecutive sales, Channing Biotech surged 15%, and Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou had advanced gains.
Express News | Fuxiang Pharmaceutical: Subsidiary passed GMP compliance inspection
Express News | Fuxiang Pharmaceutical: net loss of 200 million yuan in 2023
Fuxiang Pharmaceutical (300497.SZ): Net profit of 1.468,500 yuan for the first quarter reversed the year-on-year loss
Gelonghui, April 28 | Fuxiang Pharmaceutical (300497.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 340 million yuan, a year-on-year decrease of 14.45%; net profit attributable to shareholders of listed companies was 1.468,500 yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 10.21 million yuan; basic earnings per share.
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
Express News | Fuxiang Pharmaceutical: The subsidiary passed IATF16949 international automotive quality management system certification
Express News | Fuxiang Pharmaceutical: The subsidiary obtained EIA approval for the comprehensive utilization of microbial proteins and resources project with an annual output of 200,000 tons (Phase I)
Fuxiang Pharmaceutical (300497.SZ): The park where the subsidiary is located has passed the Jiangxi Chemical Industry Park certification
Gelonghui, Feb. 29丨Fuxiang Pharmaceutical (300497.SZ) announced. Recently, the Jiangxi Provincial Department of Industry and Information Technology issued the “Notice on Announcing the Certification Results of Yushan Pharmaceutical Industrial Park in Jingdezhen Ceramics Industrial Park”. According to the requirements of the “Jiangxi Chemical Park Construction Standards and Accreditation Administration Implementation Rules (Trial)”, according to the work procedures stipulated in the “Jiangxi Chemical Park Accreditation Work Process (Trial)” and “Notice on Simplifying the Jiangxi Chemical Park Accreditation Work Process”, Yushan Pharmaceutical Industrial Park in Jingdezhen Ceramics Industrial Park passed the certification with the approval of the Jiangxi Provincial People's Government.
Fuxiang Pharmaceutical (300497.SZ): Li Huiyue increased her holdings by a total of 100,000 shares
Gelonghui, Feb. 28 | Fuxiang Pharmaceutical (300497.SZ) announced that as of the date of this announcement, Mr. Li Huiyue had increased his holdings by 100,000 shares through centralized bidding, to an increase of 915,000 yuan. His current plan to increase his holdings has been completed.
Fuxiang Pharmaceutical (300497.SZ): Deputy General Manager Dai Zhenliang completed an increase of 80,000 shares
Gelonghui, Feb. 21丨Fuxiang Pharmaceutical (300497.SZ) announced that recently, the company received a notice from Mr. Dai Zhenliang, the deputy general manager, that the increase in the company's shares has been completed. As of the announcement date, Mr. Dai Zhenliang increased his holdings of the company by 80,000 shares through centralized bidding, to an increase of 592,600 yuan. The plan to increase his holdings has already been completed.
Fuxiang Pharmaceutical (300497.SZ): Financial Director Yang Guang completed an increase of 47,600 shares
Gelonghui, Feb. 20 | Fuxiang Pharmaceutical (300497.SZ) announced that recently, the company received a notice from the financial director, Mr. Yang Guang, that it has completed the implementation of increasing its shareholding in the company. As of the date of this announcement, Mr. Yang Guang increased his holdings of the company by 47,600 shares through centralized bidding, to an increase of 301,940 yuan. The plan to increase his holdings has already been completed.
Fushine Pharma's Unit Gets Nod for Tazobactam Sodium
Jiangxi Fushine Pharmaceutical's (SHE:300497) unit, Jiangxi Xiangtai Life Sciences, received approval from China's National Medical Products Administration to register tazobactam sodium. The drug can
Analysis
Price Target
No Data
